Beranda › Kanker (semua jenis) › New York › Buffalo
Uji klinis Kanker (semua jenis) di Buffalo, NY
19 studi untuk Kanker (semua jenis) mencari peserta di lokasi sekitar Buffalo (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study of ASP3082 in Adults With Advanced Solid Tumors
Menerima pesertaFase 1
- Roswell Park Cancer Institute, Buffalo
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Menerima pesertaFase 3
- Quetzal Site 4, Buffalo
Intratumoral N17350 in Advanced Solid Tumors
Menerima pesertaFase 1/2
- Roswell Park Comprehensive Cancer Center, Buffalo
Generating Novel Translational and Therapeutic Strategies Based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board (pedsETB)
Menerima pesertaStudi observasional
- Roswell Park Comprehensive Cancer Center, Buffalo
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Menerima pesertaFase 2/3
- Roswell Park Cancer Institute, Buffalo
Collection of Tissue Samples for Cancer Research
Menerima pesertaStudi observasional
- Roswell Park Cancer Institute, Buffalo
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
Menerima pesertaFase 2
- Roswell Park Center Institute, Buffalo
Project: Every Child for Younger Patients With Cancer
Menerima pesertaStudi observasional
- Roswell Park Cancer Institute, Buffalo
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Menerima pesertaFase 1
- Roswell Park Cancer Institute, Buffalo
Childhood Cancer Survivor Study
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Roswell Park Cancer Institute, Buffalo
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Menerima pesertaFase 1
- Roswell Cancer Institute, Buffalo
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Menerima pesertaFase 2
- Roswell Park Cancer Institute, Buffalo
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Menerima pesertaFase 1
- Roswell Park, Buffalo
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Menerima pesertaFase 1/2
- Roswell Park Comprehensive Cancer Center, Buffalo
A Pilot and Feasibility Study of a Dietary Intervention With Low-protein Meals in Cancer Patients Receiving Immunotherapies
Menerima peserta
- University at Buffalo / Great Lakes Cancer Care, Buffalo
Cannabis Use and Outcomes in Black and White Patients With Cancer
Menerima pesertaStudi observasional
- University at Buffalo, Buffalo
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Buffalo
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Menerima peserta
- Roswell Park Cancer Institute, Buffalo
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Menerima pesertaFase 1/2
- Roswell Park Cancer Institute, Buffalo
Uji klinis Kanker (semua jenis) di kota lain
- Houston, TX121 studi
- New York City, NY110 studi
- Boston, MA86 studi
- Los Angeles, CA73 studi
- Nashville, TN65 studi
- Philadelphia, PA59 studi
- Durham, NC58 studi
- Washington, DC58 studi
- Chicago, IL51 studi
- Seattle, WA49 studi
- Atlanta, GA49 studi
- Arlington, VA48 studi
Studi lain di Buffalo
- Leukemia Mieloid Akut19 studi
- Kanker Paru Non-Sel Kecil18 studi
- Kanker Paru16 studi
- Kanker Payudara16 studi
- Kanker Ovarium13 studi
- Kanker Prostat11 studi
- Kanker Metastatik11 studi
- Mieloma Multipel10 studi
- Melanoma10 studi
- Obesitas9 studi
- Limfoma Burkitt8 studi
- Sindrom Mielodisplastik8 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.